Treatment of Atypical Hidradenitis Suppurativa with the Tumor Necrosis Factor Receptor-Fc Fusion Protein Etanercept
November 2006 | Volume 5 | Issue 10 | Case Reports | 1010 | Copyright © November 2006
Robert L Henderson Jr. MD
Abstract
We present a case where etanercept—a soluble tumor necrosis factor receptor-Fc fusion protein—was safe and effective in treating
the painful skin lesions of a 24-year-old patient with hidradenitis suppurativa, resulting in an improvement in quality of life. 
